Revenue remaining performance obligations, related to unfulfilled product purchase orders
Halozyme Therapeutics·Products & Services·1 segment
Breakdown
Segments
Product sales, netView metric
| Segment | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 |
|---|---|---|---|---|---|---|---|---|
| Product sales, net | $84.3M | $79.2M | $99.9M | $154.2M | $179.3M | $260.9M | $289.5M | $265.8M |
| Total | $84.3M | $79.2M | $99.9M | $154.2M | $179.3M | $260.9M | $289.5M | $265.8M |